Avalo Therapeutics (AVTX) Non-cash Items (2015 - 2016)
Avalo Therapeutics posted quarterly Non-cash Items of $657099.0 for Q3 2016, up 49.47% year-on-year from $439607.0 in Q4 2015, and up 2.27% on a QoQ basis from $642541.0 in Q2 2016.
Avalo Therapeutics (AVTX) has 2 years of Non-cash Items data on file, last reported at $657099.0 in Q3 2016.
- For the quarter ending Q3 2016, Non-cash Items rose 49.47% year-over-year to $657099.0; the trailing twelve-month figure through Sep 2016 stood at $657099.0 (up 49.47% YoY), and the FY2015 full-year result was $604167.0, changed N/A from the prior year.
- Non-cash Items for Q3 2016 stood at $657099.0, up from $642541.0 in the prior quarter.
- Across five years, Non-cash Items topped out at $657099.0 in Q3 2016 and bottomed at $439607.0 in Q3 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2016 | 657,099.00 |
| Sep 30, 2016 | 657,099.00 |
| Jun 30, 2016 | 642,541.00 |
| Jun 30, 2016 | 642,541.00 |
| Mar 31, 2016 | 606,647.00 |
| Mar 31, 2016 | 606,647.00 |
| Dec 31, 2015 | 604,167.00 |
| Dec 31, 2015 | 604,167.00 |
| Sep 30, 2015 | 439,607.00 |
| Sep 30, 2015 | 439,607.00 |